CandlesenseCandlesense
GSK•benzinga•

GSK Raises FY2025 Adj EPS Guidance from $4.18-$4.26 to $4.25-$4.59 vs $4.36 Est; Raises FY2025 Sales Guidance from $40.07B-$40.85B to $40.68B-$42.71B vs $32.61B Est

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on April 30, 2025 by benzinga

← Back to GSK News
    GSK Raises FY2025 Adj EPS Guidance from $4.18-$4.26 to $4.25-$4.59 vs $4.36 Est; Raises FY2025 Sales Guidance from $40.07B-$40.85B to $40.68B-$42.71B vs $32.61B Est | GSK Stock News | Candlesense